A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer

European Journal of Cancer

Volumn 51, Issue 13, 2015, Pages 1714-1724

  Hussain, Maha ^a   Rathkopf, Dana ^b   Liu, Glenn ^c   Armstrong, Andrew ^d   Kelly, Wm Kevin ^e   Ferrari, Anna ^f   Hainsworth, John ^g   Joshi, Adarsh ^h   Hozak, Rebecca R ^h   Yang, Ling ^h   Schwartz, Jonathan D ^h   Higano, Celestia S ⁱ  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d DUKE CANCER INSTITUTE   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g SARAH CANNON RESEARCH INSTITUTE   (United States)

^h ELI LILLY AND COMPANY   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cixutumumab; Mitoxantrone; Prednisone; Prostate cancer; Ramucirumab

Indexed keywords

CIXUTUMUMAB; DOCETAXEL; INTERLEUKIN 8; MITOXANTRONE; PLACENTAL GROWTH FACTOR; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RAMUCIRUMAB; VASCULOTROPIN A; ANTI-IGF-1R ANTIBODY A12; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECCHYMOSIS; FATIGUE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; ADENOCARCINOMA; ADOLESCENT; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MITOXANTRONE; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84938749080     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.05.019     Document Type: Article

References (36)

1. I.F. Tannock, R. deWit, W.R. Berry, J. Horti, A. Pluzanska, K.N. Chi, and et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
2. D.P. Petrylak, C.M. Tangen, M.H. Hussain, P.N. Lara Jr, J.A. Jones, M.E. Taplin, and et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
3. A. Alva, and M. Hussain The changing natural history of metastatic prostate cancer Cancer J 19 2013 19 24
4. H.M. Khandwala, I.E. McCutcheon, A. Flyvbjerg, and K.E. Friend The effects of insulin-like growth factors on tumorigenesis and neoplastic growth Endocr Rev 21 2000 215 244
5. M. Kawada, H. Inoue, T. Masuda, and D. Ikeda Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer Cancer Res 66 2006 4419 4425
6. C. Bähr, and B. Groner The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function Growth Factors 23 2005 1 14
7. L. Mauro, M. Salerno, C. Morelli, T. Boterberg, M.E. Bracke, and E. Surmacz Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression J Cell Physiol 194 2003 108 116
8. M. Montagnani Marelli, R.M. Moretti, P. Procacci, M. Motta, and P. Limonta Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling Int J Oncol 28 2006 723 730
9. J. Rubin, L.W. Chung, X. Fan, L. Zhu, T.C. Murphy, M.S. Nanes, and et al. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis Prostate 58 2004 41 49
10. G. Blum, A. Gazit, and A. Levitzki Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics J Biol Chem 278 2003 40442 40454
11. P. Burfeind, C.L. Chernicky, F. Rininsland, and J. Ilan Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo Proc Natl Acad Sci USA 93 1996 7263 7268
12. G. Pandini, R. Mineo, F. Frasca, C.T. Roberts Jr, M. Marcelli, R. Vigneri, and et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells Cancer Res 65 2005 1849 1857
13. D. Burtrum, Z. Zhu, D. Lu, D.M. Anderson, M. Prewett, D.S. Pereira, and et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo Cancer Res 63 2003 8912 8921
14. J.D. Wu, A. Odman, L.M. Higgins, K. Haugk, R. Vessella, D.L. Ludwig, and et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors Clin Cancer Res 11 2005 3065 3074
15. J.D. Wu, K. Haugk, I. Coleman, L. Woodke, R. Vessella, P. Nelson, and et al. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors Clin Cancer Res 12 20 Pt 1 2006 6153 6160
16. E.K. Rowinsky, J.D. Schwartz, N. Zojwalla, H. Youssoufian, F. Fox, P. Pultar, and et al. Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers Curr Drug Targets 12 2011 2016 2033
17. C. Higano, J. Alumkal, C.J. Ryan, E.Y. Yu, T.M. Beer, K. Chandrawansa, and et al. A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastatic, asymptomatic castration-resistant prostate cancer (CRPC) J Clin Oncol 27 suppl 15S 2009 abstr 5142
18. J.A. Doll, F.K. Reiher, S.E. Crawford, M.R. Pins, S.C. Campbell, and N.P. Bouck Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate Prostate 49 2001 293 305
19. C. Hwang, and E.I. Heath Angiogenesis inhibitors in the treatment of prostate cancer J Hematol Oncol 3 2010 26
20. D. Strohmeyer, C. Rössing, A. Bauerfeind, O. Kaufmann, H. Schlechte, G. Bartsch, and et al. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer Prostate 45 2000 216 224
21. M. Borre, B. Nerstrøm, and J. Overgaard Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting Clin Cancer Res 6 2000 1882 1890
22. R.A. Bok, S. Halabi, D.T. Fei, C.R. Rodriquez, D.F. Hayes, N.J. Vogelzang, and et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study Cancer Res 61 2001 2533 2536
23. P. Sweeney, T. Karashima, S.J. Kim, D. Kedar, B. Mian, S. Huang, and et al. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production Clin Cancer Res 8 2002 2714 2724
24. J.L. Spratlin, R.B. Cohen, M. Eadens, L. Gore, D.R. Camidge, S. Diab, and et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 J Clin Oncol 28 2010 780 787
25. J. Spratlin Ramucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelial growth factor receptor-2 Curr Oncol Rep 13 2011 97 102
26. I.F. Tannock, D. Osoba, M.R. Stockler, D.S. Ernst, A.J. Neville, M.J. Moore, and et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
27. H.I. Scher, S. Halabi, I. Tannock, M. Morris, C.N. Sternberg, M.A. Carducci, and et al. Design and end points of phase 2 trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group (PCWG2) J Clin Oncol 26 2008 1148 1159
28. C.N. Sternberg, D. Petrylak, F. Witjes, J. Ferrero, J. Eymard, S. Falcon, and et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial J Clin Oncol 25 suppl 18S 2007 abstr 5019
29. C.N. Sternberg, D.P. Petrylak, O. Sartor, J.A. Witjes, T. Demkow, J.M. Ferrero, and et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial J Clin Oncol 27 2009 5431 5438
30. J.S. de Bono, S. Oudard, M. Ozguroglu, S. Hansen, J.P. Machiels, I. Kocak, and et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
31. E.Y. Yu, H. Li, C.S. Higano, N. Agarwal, S.K. Pal, A. Alva, and et al. SWOG S0925: a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer J Clin Oncol 33 2015 1601 1608
32. C.S. Fuchs, J. Tomasek, C.J. Yong, F. Dumitru, R. Passalacqua, C. Goswami, and et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial Lancet 383 2014 31 39
33. H. Wilke, K. Muro, Cutsem E. Van, S.C. Oh, G. Bodoky, Y. Shimada, and et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Lancet Oncol 15 2014 1224 1235
34. J. Tabernero, A.L. Cohn, R. Obermannova, G. Bodoky, R. Garcia-Carbonero, T.-E. Ciuleanu, and et al. RAISE: a randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp) J Clin Oncol 33 suppl 3 2015 abstr 512
35. E.B. Garon, T.E. Ciuleanu, O. Arrieta, K. Prabhash, K.N. Syrigos, T. Goksel, and et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Lancet 384 2014 665 673
36. D.P. Petrylak, S.T. Tagawa, M. Kohli, S. Tang, H. Zhang, O. Hamid, and et al. Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma J Clin Oncol 33 suppl 7 2015 abstr 295